en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2022
vol. 97
 
Share:
Send email
Share:
abstract:
Special paper

Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology, and Polish Society of Colposcopy and Pathophysiology of the Uterine Cervix on prophylactic vaccinations against infections with human papillomaviruses in Poland

Andrzej Nowakowski
1, 2
,
Robert Jach
3
,
Leszek Szenborn
4
,
Mariusz Bidziński
5, 6
,
Teresa Jackowska
7
,
Jan Kotarski
8
,
Agnieszka Mastalerz-Migas
9
,
Aneta Nitsch-Osuch
10
,
Jarosław Pinkas
11
,
Włodzimierz Sawicki
12
,
Piotr Sieroszewski
13
,
Maciej Stukan
14, 15
,
Jacek Wysocki
16

  1. Cervical Cancer Prevention Clinic, Central Coordinating Centre for Cervical Cancer Screening Programme, Department of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Obstetrics and Gynaecology Ward, District Specialist Hospital, Siedlce, Poland
  3. Department of Endocrine Gynaecology, Collegium Medicum of the Jagiellonian University, Cracow, Poland; President of the Polish Society for Colposcopy and Cervical Pathophysiology, Vice President of the Polish Society of Gynaecologists and Obstetricians, Chairman of the Cervical Pathology, Colposcopy and Cytology Section of the Polish Society of Gynaecologists and Obstetricians, Member of the Board of the Polish Society of Oncological Gynaecology (PTGO), and Chairman of the Section for the prevention and treatment of cervical cancer at PTGO
  4. Clinical Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; Polish Vaccinology Society
  5. Department of Oncological Gynaecology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; National Consultant in Oncological Gynaecology
  6. Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland
  7. Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland; National Consultant in the field of Paediatrics, Polish Paediatric Society
  8. Medical University in Lublin, Lublin, Poland; Polish Society of Oncological Gynaecology
  9. Chair and Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; National Consultant in Family Medicine
  10. Department of Social Medicine and Public Health, Warsaw Medical University, Warsaw, Poland; Polish Society of Family Medicine
  11. School of Public Health, Medical Centre of Postgraduate Education, Warsaw, Poland; National Consultant in Public Health
  12. Chair and Department of Obstetrics, Women’s Diseases and Oncological Gynaecology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland; President of the Polish Society of Oncological Gynaecology
  13. First Department of Gynaecology and Obstetrics, Medical University of Lodz, Lodz, Poland; President of the Polish Society of Gynaecologists and Obstetricians
  14. Department of Gynaecological Oncology, Pomeranian Hospitals, Gdynia, Poland; Vice President of the Polish Society for Colposcopy and Cervical Pathophysiology
  15. Division of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland
  16. Observation and Infectious Diseases Department of the Specialist Mother and Child Healthcare Group in Poznan, Chair and Department of Health Prophylaxis, Medical University of Poznan, Poznan, Poland; Polish Society of Vaccinology
Pediatr Pol 2022; 97 (3): 167-175
DOI: https://doi.org/10.5114/polp.2022.120124
Online publish date: 2022/10/18
View full text Get citation
 
PlumX metrics:
Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, and penile cancers, some head and neck cancers, and genital warts (condylomas). The fraction HPV-related cancers ranges from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunization programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out of pocket or in free- of-charge, local-governmental prevention programmes, but the vaccination coverage of the target population does not exceed 10%. In November 2021, one of the vaccines became available with a 50% reimbursement, work is underway to reimburse the next ones, and the National Oncology Strategy assumes the implementation of the HPV immunization programmes and vaccination of 60% of the teenage population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes is almost 100%, provided that full post-vaccination immunity is obtained before contact with the virus. Girls aged 11–13 years are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunization in the Preventive Immunization Programme (PIP) for all adolescents should be pursued. Persons over the age of 13 years may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated.
keywords:

human papillomavirus, prophylactic vaccination, cervical cancer